Showing 917 results
-
Press release /Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17 months…
-
Press release /New oral suspension formulation, designed for younger children with rare blood disorder, is now approved For about one in four children with ITP, the condition persists for more than 12…
-
Press release /Community Partnership Day symbolizes the company's commitment to improving people's lives and serving our local communities Follow the excitement with #NovartisCPD2017 and #proudmoments2017 via…
-
Press release /Ultibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the…
-
Press release /Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-free…
-
Press release /Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in…
-
Story /A new type of medicine that targets RNA was discovered by accident and could change the way some diseases are treated.
-
Press release /Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs.…
-
Press release /In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance[1] Zykadia benefit was also seen…